{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:54:42Z","timestamp":1769525682477,"version":"3.49.0"},"reference-count":61,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pain Manag."],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.2217\/pmt-2020-0030","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T09:22:28Z","timestamp":1607505748000},"page":"101-112","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Galcanezumab for the Prevention of Migraine"],"prefix":"10.1080","volume":"11","author":[{"given":"Lindsay M","family":"Frerichs","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd.Dallas, TX75390, USA"},{"name":"Department of\u00a0Neurology at Washington University School of Medicine in St. Louis, 660 S. Euclid Ave.Saint Louis, MO63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-6158","authenticated-orcid":false,"given":"Deborah I","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd.Dallas, TX75390, USA"},{"name":"Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd.Dallas, TX75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2012.00530.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01986.x"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00631.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.07.004"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0373-15.2015"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000831"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1940.02280070051003"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1940.01210040002001"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.902230105"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"issue":"3","key":"e_1_3_2_21_1","first-page":"230","article-title":"Neuropeptides in the cerebral circulation","volume":"1","author":"Uddman R","year":"1989","unstructured":"Uddman R , EdvinssonL. Neuropeptides in the cerebral circulation. Cerebrovasc. Brain Metab. Rev.1(3), 230\u2013252 (1989).","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418786261"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00188214"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.03.010"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410370873"},{"key":"e_1_3_2_33_1","unstructured":"Eli Lilly and Company\n. Emgality: highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761063s000lbl.pdf"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.224212"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00740"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1511"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011413894"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0181-6"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13432"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419840780"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70128-0"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417747230"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"issue":"1","key":"e_1_3_2_50_1","first-page":"7","article-title":"Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in Phase III studies (EVOLVE-1 & EVOLVE-2)","volume":"20","author":"Silberstein SD","year":"2019","unstructured":"Silberstein SD , StaufferVL , DayKA , LipsiusS , WilsonMC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in Phase III studies (EVOLVE-1 & EVOLVE-2). J. Headache Pain20(1), 7 (2019).","journal-title":"J. Headache Pain"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14114"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14102"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13443"},{"key":"e_1_3_2_54_1","doi-asserted-by":"crossref","unstructured":"Mulleners WM KimB-K L\u00e1inezMJAet al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre-randomized double-blind placebo-controlled Phase 3b trial. Lancet Neurol 19(10) 814-825 (2020).","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"e_1_3_2_55_1","volume-title":"World Congress of Neurology","author":"Maizels M","year":"2019","unstructured":"Maizels M , BuseD , JedynakJP , HandA , FordJH , DetkeH. Assesment of anxiety and depression in a randomized, double-blind, placebo-controlled study of galcanezumab in adults with treatment-resistant migraine: results from the conquer study. Presented at: World Congress of Neurology. Dubai, UAE, 27\u201331 October 2019."},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"e_1_3_2_57_1","unstructured":"Ellis A OtunonyeI KumarVet al. Final evidence report \u2013 CGRP inhibitors for episodic or chronic migraine. Institute for Clinical and Economic Review. (2018). https:\/\/icer-review.org\/wp-content\/uploads\/2017\/11\/ICER_Migraine_Final_Evidence_Report_070318.pdf"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"issue":"15","key":"e_1_3_2_59_1","first-page":"P2.10","article-title":"One-year treatment with galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study (P2.10-010)","volume":"92","author":"Detke H","year":"2019","unstructured":"Detke H , Pozo-RosichP , ReuterUet al. One-year treatment with galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study (P2.10-010). Neurology92(Suppl. 15), P2.10\u2013010 (2019).","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_2_60_1","first-page":"58","article-title":"CGRP monoclonal antibodies for chronic migraine: year 1 of clinical use. The author reports on early clinical experience with Emgality and AJOVY, including switching from one CGRP inhibitor to another and future considerations","volume":"19","author":"Robbins L","year":"2020","unstructured":"Robbins L . CGRP monoclonal antibodies for chronic migraine: year 1 of clinical use. The author reports on early clinical experience with Emgality and AJOVY, including switching from one CGRP inhibitor to another and future considerations. Pract. Pain Manag.19(6), 58\u201362 (2020).","journal-title":"Pract. Pain Manag."},{"key":"e_1_3_2_61_1","unstructured":"Eli Lilly and Company\n. New releases. (2019). https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-launch-triumph-first-long-term-real-world"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13684"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-1609-7"}],"container-title":["Pain Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pmt-2020-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:40:52Z","timestamp":1716000052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pmt-2020-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.2217\/pmt-2020-0030"],"URL":"https:\/\/doi.org\/10.2217\/pmt-2020-0030","relation":{},"ISSN":["1758-1869","1758-1877"],"issn-type":[{"value":"1758-1869","type":"print"},{"value":"1758-1877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}